
	<!DOCTYPE html>
	<html>
		<head>
			<title>【天风医药】长春高新：中报业绩稳健增长，长效占比持续提升</title>
			<meta charset="utf-8" />
		</head>
		<body>
			<div class="note-wrapper">
				<h1>【天风医药】长春高新：中报业绩稳健增长，长效占比持续提升</h1>
				<button class="btn btn-primary"><a href="../index.html">返回主页</a></button><br><br>
				【天风医药】长春高新：中报业绩稳健增长，长效占比持续提升<br><br>2022年8月26日，公司发布2022年半年报：2022H1实现营业收入58.31亿元，同比增长17.50%；实现归母净利润21.20亿元，同比增长10.21%；实现扣非归母净利润20.99亿元，同比增长9.20%；经营活动产生的现金流净额为9.12亿元，同比下降30.13%。二季度实现营业收入28.57亿元，同比增长6.53%；实现归母净利润9.82亿元，同比下降6.42%。<br><br>1）金赛药业实现收入49.62亿元（+31%），归母净利润21.91亿元（+18%），业绩稳健增长。Q2公司克服疫情影响，长效生长激素新患者占比稳步增长；以长效注射笔获批为切入点，强化儿科及成人领域营销推广。2）百克生物实现收入4.41亿元，归母净利润0.74亿元。3）华康药业实现收入3.05亿元，归母净利润0.16亿元。4）高新地产实现收入2.19亿元，归母净利润0.18亿元。<br><br>2022年上半年公司毛利率为89.41%，同比上升3.37 pcts；净利率为35.27%，同比下降5.76pcts。公司2022年上半年销售费用率为30.23%，同比上升2.87pcts；管理费用率为6.00%，同比增加1.37pcts，管理费用增加主要是本期职工薪酬增加所致，整体看公司费用控制较好。经营活动产生的现金流净额的减少主要由于支付职工薪酬及税费增加。<br><br>生长激素产品适应症拓展持续，注射用醋酸曲普瑞林微球、金妥昔单抗注射液等产品III期临床研发进展顺利。公司在抗衰老、医美方面，公司将基于皮肤科相关的独家产品金扶宁，积极推动医美领域相关产品销售渠道、皮肤科潜在应用产品等方面投资并购工作。<br><br>更多情况欢迎联系 天风医药 杨松/张雪<br><br>#文字纪要#
				<br><br><button class="btn btn-primary"><a href="../index.html">返回主页</a></button>
	
			</div>
			<script type="text/javascript">
				(function() {
	
		var doc_ols = document.getElementsByTagName("ol");
	
		for ( i=0; i<doc_ols.length; i++) {
	
			var ol_start = doc_ols[i].getAttribute("start") - 1;
			doc_ols[i].setAttribute("style", "counter-reset:ol_counter " + ol_start + ";");
	
		}
	
	})();
	
			</script>
			<style>
				html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr,th,td,article,aside,canvas,details,embed,figure,figcaption,footer,header,hgroup,menu,nav,output,ruby,section,summary,time,mark,audio,video{margin:0;padding:0;border:0;font:inherit;font-size:100%;vertical-align:baseline}html{line-height:1}ol,ul{list-style:none}table{border-collapse:collapse;border-spacing:0}caption,th,td{text-align:left;font-weight:normal;vertical-align:middle}q,blockquote{quotes:none}q:before,q:after,blockquote:before,blockquote:after{content:"";content:none}a img{border:none}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}*{-moz-box-sizing:border-box;-webkit-box-sizing:border-box;box-sizing:border-box}html{font-size:87.5%;line-height:1.57143em}html{font-size:14px;line-height:1.6em;-webkit-text-size-adjust:100%}body{background:#fcfcfc;color:#545454;text-rendering:optimizeLegibility;font-family:"AvenirNext-Regular"}a{color:#de4c4f;text-decoration:none}h1{font-family:"AvenirNext-Medium";color:#333;font-size:1.6em;line-height:1.3em;margin-bottom:.78571em}h2{font-family:"AvenirNext-Medium";color:#333;font-size:1.3em;line-height:1em;margin-bottom:.62857em}h3{font-family:"AvenirNext-Medium";color:#333;font-size:1.15em;line-height:1em;margin-bottom:.47143em}p{margin-bottom:1.57143em;hyphens:auto}hr{height:1px;border:0;background-color:#dedede;margin:-1px auto 1.57143em auto}ul,ol{margin-bottom:.31429em}ul ul,ul ol,ol ul,ol ol{margin-bottom:0px}ol{counter-reset:ol_counter}ol li:before{content:counter(ol_counter) ".";counter-increment:ol_counter;color:#e06e73;text-align:right;display:inline-block;min-width:1em;margin-right:0.5em}b,strong{font-family:"AvenirNext-Bold"}i,em{font-family:"AvenirNext-Italic"}code{font-family:"Menlo-Regular"}.text-overflow-ellipsis{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.sf_code_string,.sf_code_selector,.sf_code_attr-name,.sf_code_char,.sf_code_builtin,.sf_code_inserted{color:#D33905}.sf_code_comment,.sf_code_prolog,.sf_code_doctype,.sf_code_cdata{color:#838383}.sf_code_number,.sf_code_boolean{color:#0E73A2}.sf_code_keyword,.sf_code_atrule,.sf_code_rule,.sf_code_attr-value,.sf_code_function,.sf_code_class-name,.sf_code_class,.sf_code_regex,.sf_code_important,.sf_code_variable,.sf_code_interpolation{color:#0E73A2}.sf_code_property,.sf_code_tag,.sf_code_constant,.sf_code_symbol,.sf_code_deleted{color:#1B00CE}.sf_code_macro,.sf_code_entity,.sf_code_operator,.sf_code_url{color:#920448}.note-wrapper{max-width:46em;margin:0px auto;padding:1.57143em 3.14286em}.note-wrapper.spotlight-preview{overflow-x:hidden}u{text-decoration:none;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#e06e73 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}s{color:#878787}p{margin-bottom:0.1em}hr{margin-bottom:0.7em;margin-top:0.7em}ul li{text-indent:-0.35em}ul li:before{content:"•";color:#e06e73;display:inline-block;margin-right:0.3em}ul ul{margin-left:1.25714em}ol li{text-indent:-1.45em}ol ol{margin-left:1.25714em}blockquote{display:block;margin-left:-1em;padding-left:0.8em;border-left:0.2em solid #e06e73}.todo-list ul{margin-left:1.88571em}.todo-list li{text-indent:-1.75em}.todo-list li:before{content:"";display:static;margin-right:0px}.todo-checkbox{text-indent:-1.7em}.todo-checkbox svg{margin-right:0.3em;position:relative;top:0.2em}.todo-checkbox svg #check{display:none}.todo-checkbox.todo-checked #check{display:inline}.todo-checkbox.todo-checked+.todo-text{text-decoration:line-through;color:#878787}.code-inline{display:inline;background:white;border:solid 1px #dedede;padding:0.2em 0.5em;font-size:0.9em}.code-multiline{display:block;background:white;border:solid 1px #dedede;padding:0.7em 1em;font-size:0.9em;overflow-x:auto}.hashtag{display:inline-block;color:white;background:#b8bfc2;padding:0.0em 0.5em;border-radius:1em;text-indent:0}.hashtag a{color:#fff}.address a{color:#545454;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#0da35e 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}.address svg{position:relative;top:0.2em;display:inline-block;margin-right:0.2em}.color-preview{display:inline-block;width:1em;height:1em;border:solid 1px rgba(0,0,0,0.3);border-radius:50%;margin-right:0.1em;position:relative;top:0.2em;white-space:nowrap}.color-code{margin-right:0.2em;font-family:"Menlo-Regular";font-size:0.9em}.color-hash{opacity:0.4}.ordered-list-number{color:#e06e73;text-align:right;display:inline-block;min-width:1em}.arrow svg{position:relative;top:0.08em;display:inline-block;margin-right:0.15em;margin-left:0.15em}.arrow svg #rod{stroke:#545454}.arrow svg #point{fill:#545454}mark{color:inherit;display:inline;padding:0.2em 0.5em;background-color:#fcffc0}img{max-width:100%;height:auto}
			</style>
		</body>
	</html>
	